Learn how cells and animal models each factor in this space.!--h2>
Enal Razvi, Ph.D.
The focus of this GEN Market & Tech analysis report is to discuss some of our data on in vitro transfection into cells in culture as well as present some in vivo transfection data (transfection into animal model systems). This report is an extension of a report on transfection that we published several months ago; the focus of that report was on in vitro transfection into cells primarily.
We present the market landscape for transfection in this report—an important front-end approach underlying the analysis of genetic constructs such as cDNAs in a biologically relevant context—i.e., in the cellular milieu.
Lipid-based transfection into cells is the most penetrant approach currently in the marketplace.
Tissue cultured cells are much more prevalent as targets for transfection as opposed to explanted primary cells.
The most important factors underlying a transfection technology are: High Transfection Efficiency, Low Cytotoxicity to Cells, and Reproducibility (across experiment).
cDNA constructs are the most penetrant genetic payload in transfection experiments currently.
Enal Razvi, Ph.D., conducted his doctoral work on viral immunology and subsequent to receiving his Ph.D. went on to the Rockefeller University in New York to serve as Aaron Diamond Post-doctoral fellow under Professor Ralph Steinman [Nobel Prize Winner in 2011 for his discovery of dendritic cells in the early-70s with Zanvil Cohn]. Subsequently, Dr. Razvi completed his research fellowship at Harvard Medical School. For the last two decades Dr. Razvi has worked with small and large companies and consulted for more than 100 clients worldwide. He currently serves as Biotechnology Analyst and Managing Director of SelectBio U.S. He can be reached at firstname.lastname@example.org.